Milestone Pharmaceuticals Future Growth
Future criteria checks 2/6
Milestone Pharmaceuticals is forecast to grow earnings and revenue by 43% and 56.9% per annum respectively while EPS is expected to grow by 45.6% per annum.
Key information
43.0%
Earnings growth rate
45.60%
EPS growth rate
| Pharmaceuticals earnings growth | 14.4% |
| Revenue growth rate | 56.9% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 14 May 2026 |
Recent future growth updates
Recent updates
FDA Approval And Shift To Self Administered Care Will Reshape This Cardiovascular Opportunity
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular focused company centered on CARDAMYST, an etripamil nasal spray for on demand treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?
Payer Constraints On Self Administered PSVT Care Will Challenge Near Term Progress Yet Offer Upside
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular-focused biopharmaceutical company with an FDA approved, self-administered intranasal therapy, CARDAMYST, for acute treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for acute cardiovascular conditions, including paroxysmal supraventricular tachycardia through its intranasal etripamil product, CARDAMYST. What are the underlying business or industry changes driving this perspective?Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality
Summary Milestone Pharmaceuticals is downgraded to 'Sell' due to limited evidence supporting CARDAMYST's market adoption over generics. CARDAMYST's lack of statistically significant reduction in ER visits and high net price challenge its payer value proposition and peak share assumptions. My modeling, even with optimistic inputs, suggests MIST is overvalued with real downside risk, especially in a 'Bear' scenario where ROI is not achieved. Cash runway may be shorter than three years due to increased burn from CARDAMYST launch and AFib-RVR trial, raising dilution risk. Read the full article on Seeking AlphaDoes Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely
Key Insights Milestone Pharmaceuticals' Annual General Meeting to take place on 13th of June CEO Joe Oliveto's total...Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Milestone...What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
A look at the shareholders of Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) can tell us which group is most powerful...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 133 | -53 | 17 | -47 | 4 |
| 12/31/2027 | 29 | -129 | -82 | -106 | 6 |
| 12/31/2026 | 7 | -112 | -81 | -81 | 6 |
| 3/31/2026 | 2 | -68 | -51 | -51 | N/A |
| 12/31/2025 | 2 | -63 | -49 | -49 | N/A |
| 9/30/2025 | N/A | -58 | -43 | -43 | N/A |
| 6/30/2025 | N/A | -56 | -40 | -40 | N/A |
| 3/31/2025 | N/A | -52 | -34 | -34 | N/A |
| 12/31/2024 | N/A | -42 | -29 | -29 | N/A |
| 9/30/2024 | N/A | -43 | -32 | -32 | N/A |
| 6/30/2024 | N/A | -48 | -37 | -37 | N/A |
| 3/31/2024 | N/A | -55 | -42 | -41 | N/A |
| 12/31/2023 | 1 | -60 | -47 | -46 | N/A |
| 9/30/2023 | 5 | -59 | -50 | -49 | N/A |
| 6/30/2023 | 6 | -59 | -49 | -49 | N/A |
| 3/31/2023 | 6 | -59 | -53 | -52 | N/A |
| 12/31/2022 | 5 | -58 | -53 | -52 | N/A |
| 9/30/2022 | 2 | -62 | -52 | -52 | N/A |
| 6/30/2022 | N/A | -62 | -50 | -50 | N/A |
| 3/31/2022 | 15 | -44 | -35 | -35 | N/A |
| 12/31/2021 | 15 | -43 | -33 | -33 | N/A |
| 9/30/2021 | 15 | -35 | -30 | -30 | N/A |
| 6/30/2021 | 15 | -32 | -28 | -28 | N/A |
| 3/31/2021 | N/A | -46 | -45 | -45 | N/A |
| 12/31/2020 | N/A | -50 | -51 | -51 | N/A |
| 9/30/2020 | N/A | -60 | -59 | -59 | N/A |
| 6/30/2020 | N/A | -60 | -60 | -60 | N/A |
| 3/31/2020 | N/A | -61 | -55 | -54 | N/A |
| 12/31/2019 | N/A | -55 | N/A | -51 | N/A |
| 9/30/2019 | N/A | -47 | N/A | -42 | N/A |
| 6/30/2019 | N/A | -40 | N/A | -39 | N/A |
| 3/31/2019 | N/A | -29 | N/A | -31 | N/A |
| 12/31/2018 | N/A | -23 | N/A | -21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MIST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MIST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MIST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MIST's revenue (56.9% per year) is forecast to grow faster than the US market (11.7% per year).
High Growth Revenue: MIST's revenue (56.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MIST's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/18 17:45 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Milestone Pharmaceuticals Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | H.C. Wainwright & Co. |
| Brandon Folkes | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |